The study evaluated the efficacy and safety of remdesivir in treating hospitalized adults with Covid-19 and lower respiratory tract infection. A double-blind, randomized, placebo-controlled trial was conducted, with 1062 patients randomly assigned to receive either remdesivir or placebo for up to 10 days. The primary outcome was the time to recovery, defined as hospital discharge or hospitalization for infection control purposes only. Patients receiving remdesivir had a median recovery time of 10 days compared to 15 days for those receiving placebo (rate ratio, 1.29; 95% CI, 1.12 to 1.49; P<0.001). Remdesivir also showed a higher likelihood of clinical improvement at day 15 (odds ratio, 1.5; 95% CI, 1.2 to 1.9) and reduced mortality by day 29 (hazard ratio, 0.73; 95% CI, 0.52 to 1.03). Serious adverse events were reported in 24.6% of patients receiving remdesivir and 31.6% of those receiving placebo. The findings suggest that remdesivir is superior to placebo in shortening the time to recovery and improving clinical outcomes in hospitalized adults with Covid-19.The study evaluated the efficacy and safety of remdesivir in treating hospitalized adults with Covid-19 and lower respiratory tract infection. A double-blind, randomized, placebo-controlled trial was conducted, with 1062 patients randomly assigned to receive either remdesivir or placebo for up to 10 days. The primary outcome was the time to recovery, defined as hospital discharge or hospitalization for infection control purposes only. Patients receiving remdesivir had a median recovery time of 10 days compared to 15 days for those receiving placebo (rate ratio, 1.29; 95% CI, 1.12 to 1.49; P<0.001). Remdesivir also showed a higher likelihood of clinical improvement at day 15 (odds ratio, 1.5; 95% CI, 1.2 to 1.9) and reduced mortality by day 29 (hazard ratio, 0.73; 95% CI, 0.52 to 1.03). Serious adverse events were reported in 24.6% of patients receiving remdesivir and 31.6% of those receiving placebo. The findings suggest that remdesivir is superior to placebo in shortening the time to recovery and improving clinical outcomes in hospitalized adults with Covid-19.